SWX:NOVNPharmaceuticals
Is It Too Late To Consider Novartis (SWX:NOVN) After Its 3 Year 41.9% Rise?
Investors may be wondering if Novartis at CHF113.54 is still offering value, or if most of the easy gains are already on the table.
The stock is up 25.9% over the last year and 41.9% over 3 years, even though it shows a 1% decline over 7 days, a 7.8% decline over 30 days, and a 4.6% return year to date.
Recent headlines have focused on Novartis as a large global pharmaceutical business, with investors watching how its product portfolio and pipeline shape long term expectations. This context...